Back

PCSK9 inhibition for acute arterial events: more than LDL lowering

European Heart Journal

25 October 2021
Organised by: Logo
Read full article
ESC Journals CORONARY ARTERY DISEASE, ACUTE CORONARY SYNDROMES, ACUTE CARDIAC CARE Acute Coronary Syndromes DISEASES OF THE AORTA, PERIPHERAL VASCULAR DISEASE, STROKE Peripheral Vascular and Cerebrovascular Disease Stroke PREVENTIVE CARDIOLOGY Risk Factors and Prevention BASIC SCIENCE

Contributors

Carl E Orringer
Carl E Orringer

Author

You may be interested in
thumbnail
Congress Presentation
Efficacy and safety of proprotein covertase subtilisin/kexin type 9 inhibitors among patients with acute coronary syndrome: a meta-analysis of randomized controlled trials
27 August 2022
thumbnail
Webinar
Lipid management pathways and ESC Guidelines
10 January 2023
thumbnail
Congress Presentation
The effect of proprotein convertase subtilisin/kexin type 9 inhibition on the plasma proteome: a SPIRE sub-study
28 August 2023
thumbnail
Congress Presentation
PCSK9 inhibitors: effectiveness of treatment and changes in background lipid-lowering therapy in a real world Italian population. The AT-TARGET-IT study
26 August 2022

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources